Abbvie makes a grab for Shire
Enlarge image


Abbvie makes a grab for Shire

08.07.2014 - Abbvie is determined to bring home British rare disease specialist Shire in a merger worth £30.1bn (€37.9bn).

In May, Abbvie Inc. initially approached Shire plc. with a merger proposal, offering £39.50 for each Shire share. The US pharma company since improved the offer twice, only to have each new offer rejected. By late June, the offer stood at an indicative value £46.26 for each Shire share. Now, Abbvie showed it means business when the US drugmaker increased the proposal once more to £51.15 (€34.36) -  approximately 11 percent more than the last one. Abbvie now offers to pay £22.44 (€28.23) in cash and 0.8568 ordinary shares of New Abbvie for each Shire share.

Besieged Shire has not yet commented on the offer, except to say that they are considering the proposal. The board of the British company with Irish headquarters had unanimously rejected the three earlier proposals, saying they fundamentally undervalued the company and its prospects. Whether the increased offer will get the board’s blessing remains to be seen. However, there is not much time left: according to the „put up or shut up“ order – which in the UK restricts the time a potential buyer has to make a firm takeover offer – Abbvie only has until July 18th to close the deal. The drugmaker with headquarters in Chicago is hoping to domicile the new joint company in the UK, thereby circumventing high corporation tax rates in the US.

Abbvie has not yet eliminated the possibility of a hostile takeover – however, experts think this unlikely. In the past, pharma companies have been reluctant to go hostile – in its recent takeover bid, Pfizer said early on it would not go down that path. Meanwhile, Abbvie has urged Shire’s shareholders to consider the offer and put pressure on the Board, adding the company was "willing to move quickly and cooperatively to engage with Shire with a view to achieving a transaction for the benefit of all shareholders". Abbvie Chairman and CEO Richard Gonzalez commented: "Abbvie has made a compelling offer to Shire that creates immediate and long-term value to shareholders of both companies. We think its shareholders should strongly encourage the Shire board to engage in constructive dialogue with Abbvie."



04.07.2014 Genentech, a member of Swiss Roche Group, is set to acquire US-biotech Seragon Pharmaceuticals Inc. With the move, Genentech will obtain the rights to investigational breast cancer treatments.


03.07.2014 Nicox S.A. is stretching beyond the European market: The French eye health specialist is set to acquire Aciex Therapeutics Inc., a US-based pharma company with several ophthalmic therapeutics nearing market maturity.


01.07.2014 Belgian antibody specialist Ablynx has raised €41.7m through a private placement of new shares and plans on boosting their range of nanobodies in development.


30.06.2014 Building on a £1.2m financing round, Celtic Renewables partners with a Belgian pilot plant to bring its bio-fuel made from whisky production residue to an industrial scale.


25.06.2014 Sun, celebrities and a scandal - the world’s largest biotech convention is getting off to an explosive start in San Diego, California.


24.06.2014 Bayer Healthcare is getting back into gene therapy with a US$252m deal aimed at the development of a haemophilia A treatment.


20.06.2014 Tomtom founder Pieter Geelen invests in Dutch biotech Ocello, the company behind a 3D mapping technology used for predicting drug behaviour in patients.


17.06.2014 The member states of the European Union have agreed on a EU-wide directive for the authorisation process of genetically modified crops – with an opt-out for individual countries.

© 2007-2014 BIOCOM


All Events


Vilnius (LT)

Life Sciences Baltics

Current issue

All issues

Product of the week


Stock list

All quotes


  • NOVACYT (F)4.99 EUR9.67%
  • CELLECTIS (F)14.00 EUR4.56%
  • PHARMING (NL)0.53 EUR3.92%


  • PROSENSA (NL)10.48 USD-16.29%
  • ANTISOMA (UK)1.32 GBP-14.84%


  • SANTHERA (CH)72.55 CHF136.7%
  • CELLECTIS (F)14.00 EUR109.0%
  • ADDEX (CH)3.62 CHF62.3%


  • THROMBOGENICS (B)8.78 EUR-51.2%
  • MERCK KGAA (D)64.18 EUR-50.1%
  • VERONA PHARMA (UK)1.20 GBP-43.4%


  • SANTHERA (CH)72.55 CHF3564.1%
  • PAION (D)2.92 EUR323.2%


  • EVOCUTIS (UK)0.21 GBP-93.3%
  • CYTOS (CH)0.25 CHF-92.8%
  • THROMBOGENICS (B)8.78 EUR-72.8%

No liability assumed, Date: 09.07.2014